Geneva, Nov. 2 -- International Clinical Trials Registry received information related to the study (NCT07889349) titled 'A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SHR 3201 Injection in Healthy Participants' on Oct. 16.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Beijing Suncadia Pharmaceuticals Co., Ltd
Condition:
Alzheimer's Disease
Intervention:
Drug: SHR 3201 Injection
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: November 2026
Target Sample Size: 50
Countries of Recruitment:
C...